TRex Bio prices $117M IPO to support immune drug work
Eli Lilly is the largest equity holder in TRex, which is developing drugs that treat immunological conditions by activating “Treg” cells.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.